BioNTech Co-Founders to Launch New mRNA Venture Amid Strategic Pivot to Oncology

Two of BioNTech’s original co-founders are set to establish a new biotechnology venture centered on next-generation mRNA platforms, according to public disclosures. The initiative, which will be headquartered in Germany, aims to expand mRNA applications beyond infectious diseases into novel therapeutic areas, including autoimmune conditions and tissue regeneration. The founders have secured initial funding of €120 million from a consortium of European and U.S.-based venture investors, including existing partners from BioNTech’s early funding rounds. BioNTech itself has intensified its focus on oncology in 2026, with its pipeline now comprising 14 clinical-stage candidates targeting solid tumors and hematologic malignancies. The company reported that 68% of its R&D budget was allocated to cancer programs in Q4 2025, up from 42% in 2023. This strategic realignment follows the Phase 3 success of its personalized cancer vaccine BNT122 in melanoma, which demonstrated a 30% reduction in recurrence risk compared to placebo. The new venture will operate independently but is expected to maintain intellectual property collaboration with BioNTech, particularly in platform technology. Shares of BNTX rose 4.7% in after-hours trading following the announcement, while MRNA and VRTX both gained 2.3% and 1.8% respectively, indicating market optimism around mRNA innovation. Analysts note that the separation of leadership may also influence investor sentiment, with some expressing concern over potential talent and IP fragmentation. The shift underscores a broader trend in the biotech sector: companies are moving beyond pandemic-era mRNA success to develop disease-specific therapies. With BioNTech now positioning itself as a leader in personalized oncolytic mRNA vaccines, the new venture could further accelerate innovation in the space—potentially reshaping competition among players like Moderna and Vertex Pharmaceuticals.